indivior plc - INDV
INDV
Close Chg Chg %
34.36 0.08 0.23%
Closed Market
34.44
+0.08 (0.23%)
Volume: 1.18M
Last Updated:
Feb 19, 2026, 4:00 PM EDT
Company Overview: indivior plc - INDV
INDV Key Data
| Open $34.44 | Day Range 33.84 - 34.63 |
| 52 Week Range 7.62 - 38.00 | Market Cap $4.31B |
| Shares Outstanding 124.77M | Public Float 120.66M |
| Beta 1.00 | Rev. Per Employee N/A |
| P/E Ratio 34.21 | EPS $1.02 |
| Yield 0.00% | Dividend $0.10 |
| EX-DIVIDEND DATE Jun 16, 2016 | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.62M |
INDV Performance
| 1 Week | -0.40% | ||
| 1 Month | 5.84% | ||
| 3 Months | 5.16% | ||
| 1 Year | 307.57% | ||
| 5 Years | N/A |
INDV Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
7
Full Ratings ➔
About indivior plc - INDV
Indivior Pharmaceuticals, Inc. is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company was founded on December 23, 2014 and is headquartered in North Chesterfield, VA.
INDV At a Glance
Indivior Pharmaceuticals, Inc.
10710 Midlothian Turnpike
North Chesterfield, Virginia 23235
| Phone | 1-804-379-1040 | Revenue | 1.19B | |
| Industry | Pharmaceuticals: Major | Net Income | 2.00M | |
| Sector | Health Technology | 2024 Sales Growth | 8.692% | |
| Fiscal Year-end | 12 / 2025 | Employees | 1,051 | |
| View SEC Filings |
INDV Valuation
| P/E Current | 34.209 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 828.667 |
| Price to Sales Ratio | 1.392 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | 45.92 |
| Enterprise Value to EBITDA | 5.44 |
| Enterprise Value to Sales | 1.438 |
| Total Debt to Enterprise Value | 0.22 |
INDV Efficiency
| Revenue/Employee | 1,130,352.046 |
| Income Per Employee | 1,902.95 |
| Receivables Turnover | 4.125 |
| Total Asset Turnover | 0.725 |
INDV Liquidity
| Current Ratio | 0.894 |
| Quick Ratio | 0.704 |
| Cash Ratio | 0.341 |
INDV Profitability
| Gross Margin | 84.007 |
| Operating Margin | 23.99 |
| Pretax Margin | 1.178 |
| Net Margin | 0.168 |
| Return on Assets | 0.122 |
| Return on Equity | N/A |
| Return on Total Capital | 7.407 |
| Return on Invested Capital | 1.487 |
INDV Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 1,388.889 |
| Total Debt to Total Assets | 28.302 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 1,285.185 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Indivior Plc - INDV
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 791.00M | 901.00M | 1.09B | 1.19B | |
Sales Growth
| +22.26% | +13.91% | +21.31% | +8.69% | |
Cost of Goods Sold (COGS) incl D&A
| 140.00M | 172.00M | 201.00M | 190.00M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 22.00M | 21.00M | 28.00M | 29.00M | |
Depreciation
| 13.00M | 14.00M | 16.00M | 12.00M | |
Amortization of Intangibles
| 9.00M | 7.00M | 12.00M | 17.00M | |
COGS Growth
| +28.44% | +22.86% | +16.86% | -5.47% | |
Gross Income
| 651.00M | 729.00M | 892.00M | 998.00M | |
Gross Income Growth
| +21.00% | +11.98% | +22.36% | +11.88% | |
Gross Profit Margin
| +82.30% | +80.91% | +81.61% | +84.01% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 464.00M | 520.00M | 634.00M | 713.00M | |
Research & Development
| 52.00M | 72.00M | 106.00M | 107.00M | |
Other SG&A
| 412.00M | 448.00M | 528.00M | 606.00M | |
SGA Growth
| +3.11% | +12.07% | +21.92% | +12.46% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| (5.00M) | 297.00M | 264.00M | 249.00M | |
EBIT after Unusual Expense
| 192.00M | (88.00M) | (6.00M) | 36.00M | |
Non Operating Income/Expense
| 24.00M | 22.00M | 45.00M | 19.00M | |
Non-Operating Interest Income
| 4.00M | 19.00M | 43.00M | 23.00M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 26.00M | 29.00M | 38.00M | 41.00M | |
Interest Expense Growth
| -0.00% | +11.54% | +31.03% | +7.89% | |
Gross Interest Expense
| 26.00M | 29.00M | 38.00M | 41.00M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| 190.00M | (95.00M) | 1.00M | 14.00M | |
Pretax Income Growth
| +209.83% | -150.00% | +101.05% | +1,300.00% | |
Pretax Margin
| +24.02% | -10.54% | +0.09% | +1.18% | |
Income Tax
| (15.00M) | (42.00M) | (1.00M) | 11.00M | |
Income Tax - Current - Domestic
| 3.00M | 64.00M | 55.00M | (6.00M) | |
Income Tax - Current - Foreign
| - | - | - | 11.00M | - |
Income Tax - Deferred - Domestic
| (18.00M) | (106.00M) | (56.00M) | 25.00M | |
Income Tax - Deferred - Foreign
| - | - | - | (19.00M) | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| 205.00M | (53.00M) | 2.00M | 2.00M | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| 205.00M | (53.00M) | 2.00M | 2.00M | |
Net Income Growth
| +238.51% | -125.85% | +103.77% | -0.00% | |
Net Margin Growth
| +25.92% | -5.88% | +0.18% | +0.17% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| 205.00M | (53.00M) | 2.00M | 2.00M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 205.00M | (53.00M) | 2.00M | 2.00M | |
EPS (Basic)
| 1.4074 | -0.3813 | 0.0146 | 0.0151 | |
EPS (Basic) Growth
| +239.39% | -127.09% | +103.83% | +3.42% | |
Basic Shares Outstanding
| 145.66M | 139.01M | 137.31M | 132.00M | |
EPS (Diluted)
| 1.3292 | -0.3813 | 0.0141 | 0.015 | |
EPS (Diluted) Growth
| +231.64% | -128.69% | +103.70% | +6.38% | |
Diluted Shares Outstanding
| 154.23M | 139.01M | 141.80M | 133.00M | |
EBITDA
| 209.00M | 230.00M | 286.00M | 314.00M | |
EBITDA Growth
| +83.33% | +10.05% | +24.35% | +9.79% | |
EBITDA Margin
| +26.42% | +25.53% | +26.17% | +26.43% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 45.571 | |
| Number of Ratings | 7 | Current Quarters Estimate | 0.65 | |
| FY Report Date | 03 / 2026 | Current Year's Estimate | 2.987 | |
| Last Quarter’s Earnings | 0.70 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 2.333 | Next Fiscal Year Estimate | 3.311 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 5 | 5 | 7 | 7 |
| Mean Estimate | 0.65 | 0.72 | 2.99 | 3.31 |
| High Estimates | 0.73 | 0.78 | 3.19 | 3.58 |
| Low Estimate | 0.59 | 0.65 | 2.65 | 3.10 |
| Coefficient of Variance | 10.60 | 7.35 | 6.05 | 5.22 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 7 | 7 | 6 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 0 | 0 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Indivior Plc - INDV
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Indivior Plc - INDV
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Feb 13, 2026 | Christian Heidbreder Chief Scientific Officer | 132,565 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 13, 2026 | Woodrow Anderson Chief Accounting Officer | 23,975 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 13, 2026 | Woodrow Anderson Chief Accounting Officer | 11,293 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 13, 2026 | Ryan Preblick Chief Financial Officer | 113,510 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 13, 2026 | Ryan Preblick Chief Financial Officer | 317,940 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 13, 2026 | Patrick A. Barry Chief Commercial Officer | 31,380 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 13, 2026 | Christian Heidbreder Chief Scientific Officer | 190,762 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 13, 2026 | Jeffrey W. Burris Chief Legal Officer | 104,300 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 13, 2026 | Jeffrey W. Burris Chief Legal Officer | 27,657 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 13, 2026 | Joseph J. Ciaffoni Chief Executive Officer; Director | 135,976 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 29, 2026 | David E. Wheadon Director | 20,350 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 29, 2026 | Stuart Anthony Kingsley Director | 4,642 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 29, 2026 | Juliet Thompson Director | 7,572 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 29, 2026 | Mark P. Stejbach Director | 20,569 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 29, 2026 | Daniel A. Ninivaggi Director | 20,645 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 29, 2026 | Keith Humphreys Director | 9,524 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 29, 2026 | Barbara Ann Ryan Director | 5,685 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 19, 2025 | Mark Crossley | N/A | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |